Keytruda (pembrolizumab)

pCPA File Number: 21649
Negotiation Status:
Under consideration for negotiation
Indication(s):
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0236-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable